DBV Technologies presented six clinical and preclinical presentations on Epicutaneaous Immunotherapy (EPIT) at the European Academy of Allergy & Clinical Immunology & World Allergy Organization & World Allergy & Asthma Congress (EAACI-WAO) in Milan, Italy. DBV's Viaskin technology was highlighted in six presentations, which included one oral presentation on DBV's ongoing phase IIb food challenge methodology, as well as multiple poster presentations on EPIT's immunological impact. DBV also presented five posters, which were related to Viaskin EPIT technology in several indications, including a model evaluating EPIT's efficacy in eosinophil gastro-intestinal disorders, a disease mainly triggered by food allergies. All abstracts are available on the EAACI website as well as on the DBV website. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the FDA.